Loading
A phase 1/2 trial of AVZO-021, Palbociclib, Fulvestrant in ovarian cancer and endometrial cancer, run by Avenzo Therapeutics, Inc., now recruiting.
Study of AVZO-021 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05867251 by Avenzo Therapeutics, Inc., with 430 participants planned, started 2023-08-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib. Conditions listed: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AVZO-021, Avenzo Therapeutics, Fulvestrant.
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Ovarian cancer.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
Shares Ribociclib, Abemaciclib, Palbociclib, Ovarian cancer.
Shares Abemaciclib, Fulvestrant, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/